178 related articles for article (PubMed ID: 34224045)
1. Definition and Prediction of Early Recurrence and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: Towards Predicting Oncologic Futility Preoperatively.
Rieser CJ; Jones H; Hall LB; Kang E; Altpeter S; Zureikat AH; Holtzman MP; Lee A; Ongchin M; Pingpank JF; Choudry MHA; Bartlett DL
Ann Surg Oncol; 2021 Dec; 28(13):9116-9125. PubMed ID: 34224045
[TBL] [Abstract][Full Text] [Related]
2. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
[TBL] [Abstract][Full Text] [Related]
3. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
[No Abstract] [Full Text] [Related]
4. Patterns and Timing of Recurrence following CRS and HIPEC in Colorectal Cancer Peritoneal Metastasis.
Hassan S; Malcomson L; Soh YJ; Wilson MS; Clouston H; O'Dwyer ST; Kochhar R; Aziz O
Eur J Surg Oncol; 2023 Jan; 49(1):202-208. PubMed ID: 35987797
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Pantelis A; Ben-Yaacov A; Adileh M; Schtrechman G; Shacham-Shmueli E; Boursi B; Margalit O; Halpern N; Mor E; Assaf D; Maximiliano K; Nissan A; Laks S
J Gastrointest Surg; 2022 Aug; 26(8):1724-1731. PubMed ID: 35768716
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
7. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study.
Livin M; Leonard D; Bachmann R; Remue C; Barbois S; Cotte E; Van Den Eynde M; De Cuyper A; Sinapi I; Van Maanen A; Kartheuser A
Acta Gastroenterol Belg; 2022; 85(4):573-579. PubMed ID: 36566366
[TBL] [Abstract][Full Text] [Related]
8. Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry.
Kelly ME; O'Sullivan NJ; Bolger JC; Polignano F; Youssef H; Renehan A; Malcomson L; Alves S; Cecil T; Mulsow J; Moran B; Mohamed F;
Br J Cancer; 2023 Jan; 128(1):42-47. PubMed ID: 36347966
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.
Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A
Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455
[TBL] [Abstract][Full Text] [Related]
10. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O
Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886
[TBL] [Abstract][Full Text] [Related]
11. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
Chang SC; Fingerhut A; Chen WT
Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
[TBL] [Abstract][Full Text] [Related]
13. Development of a prediction model for recurrence in patients with colorectal peritoneal metastases undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Dietz MV; Hannink G; Said I; van der Zant FA; van de Vlasakker VCJ; Brandt-Kerkhof ARM; Verhoef C; Bremers AJA; de Wilt JHW; Hemmer PHJ; de Hingh IHJT; de Reuver PR; Madsen EVE
Eur J Surg Oncol; 2024 Jun; 50(6):108294. PubMed ID: 38583215
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer.
Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Calegari MA; Martini M; Rotolo S; Pacelli F
J Gastrointest Surg; 2021 Oct; 25(10):2649-2659. PubMed ID: 34244953
[TBL] [Abstract][Full Text] [Related]
15. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
16. Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A systematic review and discussion of latest controversies.
Flood M; Narasimhan V; Waters P; Ramsay R; Michael M; Warrier S; Heriot A
Surgeon; 2021 Oct; 19(5):310-320. PubMed ID: 33023847
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
[TBL] [Abstract][Full Text] [Related]
18. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
[TBL] [Abstract][Full Text] [Related]
19. In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival.
Said I; Ubink I; Ewalds RSG; Arkesteijn JGT; Verheul HMW; de Wilt JHW; Dekker HM; Bremers AJA; de Reuver PR
Ann Surg Oncol; 2022 Aug; 29(8):5256-5262. PubMed ID: 35430666
[TBL] [Abstract][Full Text] [Related]
20. Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis.
Chidambarasamy ES; Chia CS; Johnny Ong CA; Soo KC; Ching Teo MC; Ching Tan GH
Asian J Surg; 2022 Jan; 45(1):339-345. PubMed ID: 34148748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
